BRISTOL-MYERS SQUIBB COMPANY Unrecognized Tax Benefits, Income Tax Penalties Expense
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Unrecognized Tax Benefits, Income Tax Penalties Expense of $4.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-21.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties › Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense · last filed 2017-02-21
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, income tax penalties expense for fiscal 2016 was $4.00M, a 300.00% increase from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, income tax penalties expense for fiscal 2015 was $1.00M.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, income tax penalties expense for fiscal 2014 was -$7.00M, a 333.33% decline from fiscal 2013.
- BRISTOL-MYERS SQUIBB COMPANY unrecognized tax benefits, income tax penalties expense for fiscal 2013 was $3.00M, a 81.25% decline from fiscal 2012.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties Expense 12 month | Unrecognized Tax Benefits, Income Tax Penalties Expense 12 month as first filed |
|---|---|---|
| 2016-12-31 | $4.00M 10-K · filed 2017-02-21 | |
| 2015-12-31 | $1.00M 10-K · filed 2017-02-21 | |
| 2014-12-31 | -$7.00M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $3.00M 10-K · filed 2016-02-12 | |
| 2012-12-31 | $16.00M 10-K · filed 2015-02-13 | |
| 2011-12-31 | $7.00M 10-K · filed 2014-02-14 | |
| 2010-12-31 | -$4.00M 10-K · filed 2013-02-15 | $4.00M 10-K · filed 2011-02-18 |
| 2009-12-31 | -$1.00M 10-K · filed 2012-02-17 | $1.00M 10-K · filed 2011-02-18 |
| 2008-12-31 | $7.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |